It seems that there may be a new Valley of Death on the horizon of COVID therapeutic development. Earlier this month (9 JUL) NIAID posted a Funding Opportunities Announcement soliciting proposals related to COVID therapeutic development through their Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern program (RFA-AI-21-050: Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern (U19 Clinical Trial Not Allowed) (nih.gov). The objective of this solicitation is to establish a program of research focused on the discovery and development of new antiviral drug candidates to generate a more robust pipeline of novel antivirals. About the same time (6 JUL) another solicitation (SAM.gov) was published seeking proposals for the delivery of 500,000 treatment courses of COVID anti-viral therapeutics. About 15 years ago BARDA was established to address the so-called Valley of Death between preclinical NIH funding and procurement for a stockpile of MCMs and it at the moment it looks like a new valley is ahead for COVID therapeutics. BARDA was very successful in bridging that valley and hopefully they will receive ARD funding to bridge this one too.
A New Valley of Death? by Eric Jia-Sobota
About EverGlade Consulting
EverGlade Consulting is a national consulting firm that helps clients navigate the federal landscape. We are inspired by technology-driven companies whose focus is to secure non-dilutive funding through the federal government. We offer services ranging from proposal support through the implementation of systems to comply with federal regulations at agencies including BARDA, the DOD, HHS, NIAID, and DTRA.